Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.56 |
| ▸ | CTSB | P07858 | 3/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 6/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465007 | 0.82 | CTSL (0.58) | CTSLCTSBCTSSCTSKTAS1R3 | |
| SCHEMBL6063613 | 0.82 | CTSL (0.54) | CTSLCTSBCTSSCTSKTAS1R3 | |
| SCHEMBL7796791 | 0.80 | CTSL (0.67) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL6062662 | 0.79 | CTSL (0.54) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL7330463 | 0.78 | CTSL (0.67) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL6462122 | 0.78 | CTSL (0.59) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL7049064 | 0.78 | CTSL (0.55) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL7768345 | 0.77 | CTSL (0.63) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL7136272 | 0.77 | CTSL (0.63) | CTSLCTSBCTSSCTSKCAPN1 | |
| SCHEMBL7764593 | 0.77 | CTSL (0.65) | CTSLCTSBCTSSCTSKCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
| EP-1161422-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000055144-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | CTSL 18/4885CTSB 11/4885CTSS 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.